The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After Hepatectomy
Conditions: Liver Neoplasms Interventions: Other: late-evening snacks Sponsors: DU Yao Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response
Conditions: Acute on Chronic Liver Failure Interventions: Biological: Plasma Exchange; Other: Standard Medical Treatment Sponsors: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase
Conditions: Cardiovascular Diseases; Cancer; Liver Diseases; Hyperthermia Interventions: Behavioral: Disease Risk Assessment Sponsors: Duke University; National Human Genome Research Institute (NHGRI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases
Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis Interventions: Drug: Silymarin; Drug: Placebo Sponsors: Phramongkutklao College of Medicine and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Conditions: Parenteral Nutrition Associated Liver Disease (PNALD); Essential Fatty Acid Deficiency; Malnutrition; Pediatric ALL Interventions: Drug: Omegaven ® (fish oil triglycerides) Injectable Emulsion Sponsors: Fresenius Kabi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection
Conditions: Liver Failure Sponsors: Zhejiang University; Beijing Ditan Hospital; Beijing YouAn Hospital; Huashan Hospital; Qilu Hospital of Shandong University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
A Multicenter, Randomized, Placebo Controlled, Double-blinded, Phase 4 to Evaluate the Efficacy and Safety of DWJ1464 in Patients With Chronic Liver Disease
Conditions: Chronic Liver Disease Interventions: Drug: DWJ1464; Drug: Placebo of DWJ1464 Sponsors: Daewoong Pharmaceutical Co. LTD. Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
Conditions: Healthy; Liver Diseases Interventions: Drug: Avenciguat (BI 685509) Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Total laparoscopic partial hepatectomy versus open partial hepatectomy for primary left-sided hepatolithiasis: study protocol for a randomized controlled trial
ConclusionsAlthough the outcomes of LLH have been proven to be comparable to those of OLH in retrospective studies, the use of LLH remains restricted, partly due to the lack of short- and long-term informative RCTs pertaining to patients with hepatolithiasis in ERAS programmes. To evaluate the surgical and long-term outcomes of LLH, we will perform a prospective RCT to compare LLH with OLH for hepatolithiasis within an ERAS programme.Trial registrationClinicalTrials.gov NCT03958825. Registered on 21 May 2019. (Source: Trials)
Source: Trials - February 22, 2024 Category: Research Source Type: clinical trials
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
Conditions: Liver Cirrhosis Interventions: Drug: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet); Drug: Zibotentan + placebo (placebo matching dapagliflozin tablet); Drug: Zibotentan + dapagliflozin Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
Conditions: Colorectal Cancer Interventions: Drug: Icaritin Combined With Bevacizumab and FOLFIRI Sponsors: Sir Run Run Shaw Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Conditions: Alcohol-related Liver Disease; Liver Diseases Interventions: Behavioral: ENGAGE-ALD Application (APP); Behavioral: Treatment Facilitation bundle; Behavioral: Enhanced Usual Care Sponsors: University of Michigan; National Institute on Alcohol Abuse and Alcoholism (NIAAA) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors
Conditions: Liver Neoplasms Interventions: Procedure: Anatomical laparoscopic liver resection for liver neoplasms; Procedure: Non-Anatomical laparoscopic liver resection for liver neoplasms Sponsors: Sohag University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.
Conditions: Liver Fibrosis; Cirrhosis, Liver; Chronic Liver Disease Interventions: Drug: Pirfenidone 1200 mg; Drug: Pirfenidone 1800 mg; Drug: Placebo Sponsors: Jorge L Poo Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
Conditions: Hepatocellular Carcinoma; Liver Cancer Stage IV; Pulmonary Metastases; Cadonilimab; Bevacizumab; Cryoablation Interventions: Drug: Cadonilimab; Drug: Bevacizumab; Procedure: Cryoablation Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
